Company intelligence / Profile preview

Aphaia Pharma

Ownership: Private
Employees: ~9
Development stage: Phase 2

Overview

Aphaia's lead drug candidate, an oral glucose formulation (APHD-012), has completed enrollment in two Phase 2 trials - one for chronic weight management in individuals with obesity and another to improve glucose tolerance in individuals with prediabetes. In a Phase 1 trial, the formulation induced therapeutically relevant release of enteric hormones including GLP-1, PYY, glicentin, and oxyntomodulin. Topline data for the obesity trial was anticipated in Q3 and Q4 2024 for Arms 1 and 2 respectively.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Oral glucose formulations
Industry: Biotech

Drug pipeline

5 assets

APHD-012

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Aphaia Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aphaia Pharma.

Explore the full profile